These findings have catalyzed further investigations into the potential use of PAPD5 small molecule inhibitors as a therapeutic strategy for PARN mutation-related disorders, such as dyskeratosis congenita (DC) [21]. This evidence concerns the gene PARN and dyskeratosis congenita.